Samsung Biologics showcased manufacturing technologies designed to accelerate biopharmaceutical development and improve product quality at BioProcess International (BPI) 2026 in Boston, highlighting efforts to streamline complex drug production. The company said Monday it participated in BPI from Sept. 22-25, drawing more than 3,000 biopharmaceutical professionals from around the world. Samsung Biologics, which has attended BPI for nine consecutive years, operated its own booth featuring capabilities spanning contract research, development and manufacturing, along with Samsung Organoids, differentiated contract development and manufacturing services and production for multiple modalities. During a presentation Wednesday, the company's antibody purification process development team outlined an integrated chemistry, manufacturing and controls strategy for bispecific and multispecific antibodies. The team said molecule-specific process development reduced a development timeline from 13 months to 9.5 months while maintaining high quality. Scientific posters presented during the conference als